- Home
- NSIT vs TGTX Comparison
NSIT vs TGTX Comparison
Compare NSIT & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSIT
- TGTX
- Stock Information
- Founded
- NSIT 1988
- TGTX 1993
- Country
- NSIT United States
- TGTX United States
- Employees
- NSIT N/A
- TGTX N/A
- Industry
- NSIT EDP Services
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- NSIT Technology
- TGTX Health Care
- Exchange
- NSIT Nasdaq
- TGTX Nasdaq
- Market Cap
- NSIT 4.7B
- TGTX 5.4B
- IPO Year
- NSIT 1995
- TGTX 1995
- Fundamental
- Price
- NSIT $157.51
- TGTX $28.88
- Analyst Decision
- NSIT Buy
- TGTX Strong Buy
- Analyst Count
- NSIT 4
- TGTX 6
- Target Price
- NSIT $212.50
- TGTX $40.67
- AVG Volume (30 Days)
- NSIT 378.1K
- TGTX 2.2M
- Earning Date
- NSIT 02-13-2025
- TGTX 02-26-2025
- Dividend Yield
- NSIT N/A
- TGTX N/A
- EPS Growth
- NSIT 9.36
- TGTX N/A
- EPS
- NSIT 7.93
- TGTX N/A
- Revenue
- NSIT $8,865,044,000.00
- TGTX $264,790,000.00
- Revenue This Year
- NSIT N/A
- TGTX $44.11
- Revenue Next Year
- NSIT $4.19
- TGTX $63.92
- P/E Ratio
- NSIT $19.85
- TGTX N/A
- Revenue Growth
- NSIT N/A
- TGTX 39.53
- 52 Week Low
- NSIT $146.56
- TGTX $12.84
- 52 Week High
- NSIT $228.07
- TGTX $36.84
- Technical
- Relative Strength Index (RSI)
- NSIT 50.59
- TGTX 41.87
- Support Level
- NSIT $152.01
- TGTX $27.55
- Resistance Level
- NSIT $155.13
- TGTX $33.55
- Average True Range (ATR)
- NSIT 4.63
- TGTX 1.52
- MACD
- NSIT 1.14
- TGTX -0.51
- Stochastic Oscillator
- NSIT 84.13
- TGTX 22.17
About NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, governments, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital innovation, cloud/data center transformation, connected workforce, and supply chain optimization solutions and services.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.